Newsfileยท2025-11-13 02:15Core Viewpoint - Rosen Law Firm is urging investors of Cytokinetics, Inc. to take action before the November 17, 2025 deadline related to a securities class action lawsuit concerning misleading statements about the company's New Drug Application for aficamten [2][6]. Group 1: Class Action Details - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - The lawsuit alleges that Cytokinetics made false statements regarding the timeline for the NDA submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [5].